Navigation Links
Hagens Berman: Patients Seek to Force FDA to Release Records Showing US Distribution of Thalidomide
Date:11/17/2011

SEATTLE, Nov. 17, 2011 /PRNewswire/ -- Attorneys representing a group of U.S. citizens suffering from severe birth defects they believe were caused by the drug thalidomide have filed a lawsuit in federal court to compel the FDA to release records they believe will show the drug was widely distributed in the United States.

The suit seeks to compel the FDA to respond to a number of Freedom of Information Act (FOIA) requests by attorneys representing the patients, some filed more than a year ago. Under Federal law, the FDA has 20 business days to respond to a FOIA.

Thalidomide is a drug marketed throughout Canada and Europe during the late 1950s and early 1960s that caused thousands of deaths and extreme, disfiguring birth defects when used by women during pregnancy.

The drug was never approved for use in the United States, but newly uncovered documents show that hundreds of women in the US may have taken the drug as part of a marketing scheme conducted by Richardson-Merrell, a US drug distributor now owned by Sanofi-Aventis (NYSE: SNY), according to a lawsuit filed by Hagens Berman. The company gave physicians across the US as many as 2.5 million doses of the drug, the lawsuit claims.

According to court documents filed by the attorneys, the FDA archives contain lists of the physicians who were part of the marketing efforts.

"The conventional wisdom in this case has been that information about thalidomide is readily available, when in reality, the FDA is withholding key information and documents," said Steve Berman, managing partner for Hagens Berman. "These documents may prove what we have believed for some time; that thalidomide was given to pregnant women throughout the United States."

The FOIA lawsuit was filed by Kay Gunderson Reeves, co-counsel with Hagens Berman, who filed a lawsuit on Oct. 25, 2011, against Sanofi-Aventis, GlaxoSmithKline, Grunenthal GMBH and Avantor Performance materials on behalf of alleged U.S. victims.

Hagens Berman's lawsuit claims that new medical advances have changed scientists understanding of how thalidomide interacts with the body. Previously, the drug was believed to operate through a neural mechanism, causing only bilateral injuries. New cancer research demonstrates that the drug may primarily impact the vascular system, allowing it to cause unilateral defects.

Hagens Berman is representing several alleged thalidomide victims with such injuries who were previously unaware that thalidomide could have been the cause.

"We think there may be hundreds of people across the United States who have serious birth defects but were told that thalidomide could not be the cause," said Berman. "Many may have suffered for years believing they were victims of poor luck, when in fact thalidomide caused their injuries."

"I would think the FDA would be driving the effort to inform, rather than block the efforts of thalidomide victims to find the truth," Berman added.

More information about Hagens Berman's cases on behalf of alleged thalidomide victims can be found at www.hbsslaw.com/thalidomide.

About Hagens Berman

Seattle-based Hagens Berman Sobol Shapiro LLP represents workers, whistleblowers, investors and consumers in complex litigation. The firm has offices in Boston, Chicago, Colorado Springs, Los Angeles, Minneapolis, New York, Phoenix, San Francisco and Washington, D.C. Founded in 1993, HBSS continues to successfully fight for investor rights in large, complex litigation. More about the law firm and its successes can be found at www.hbsslaw.com. Visit the firm's class-action law blog at www.classactionlawtoday.com.

Contact: Mark Firmani, Firmani + Associates Inc., 206.443.9357 or mark@firmani.com.


'/>"/>
SOURCE Hagens Berman
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
3. Millennium Initiates Clinical Trial to EVOLVE the Treatment of Patients with Newly Diagnosed Multiple Myeloma
4. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
5. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
6. Sixty-One Percent of Newly Diagnosed Parkinsons Disease Patients Do Not Receive Any Drug Treatment in the First Year of Diagnosis
7. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
8. Many Heart Attack Patients Dont Get Best Emergency Treatment
9. Video: Landmark Study in The Lancet: Patients Treated With Betaseron(R) After First MS Attack Experienced Significant Delay in MS Progression
10. Phase 2a Multi-Dose Study Initiated by MedImmune in Patients With Asthma to Further Expand Anti-Interleukin-9 Program
11. MedImmune Initiates Phase 2a Multi-Dose Study in Patients with Asthma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/12/2017)... Divoti USA will engrave and process all non-coated stainless ... FDA requirements, which stipulates new criteria regarding medical device manufacture and ... ID jewelry such as Medical ID Bracelets, can rest assured that ... the new FDA requirements . ... Divoti offers this dark mark fiber laser engraving process with ...
(Date:10/11/2017)... , Oct. 11, 2017  BioPharmX Corporation (NYSE MKT: ... that developed an innovative way to use nonlinear optical ... delivery of new drugs. ... Dermatology Conference will show how researchers from BioPharmX and ... Medical School used a suite of imaging techniques in ...
(Date:10/11/2017)...  True Health, a leader in integrated diagnostics ... National Breast Cancer Awareness month to educate doctors ... Research recently published in ... than 10 million American women are at significant ... BRCA2 and have not had testing. These mutations can ...
Breaking Medicine Technology:
(Date:10/13/2017)... Nevada (PRWEB) , ... October 13, 2017 , ... ... Hemp CBD Oil utilizing Purzorb™ technology. Applying the Purzorb™process to full spectrum CBD oil ... required and providing a CBD form that can be easily incorporated into liquid products, ...
(Date:10/13/2017)... Calif. (PRWEB) , ... October 13, 2017 , ... Many ... dementia. However, many long-term care insurance companies have a waiver for care if the ... 90-day elimination period, when the family pays for care, is often waived, so the ...
(Date:10/13/2017)... ... ... Yisrayl Hawkins, Pastor and Overseer at The House of Yahweh, has released a ... books in the Holy Scriptures, Revelation. The Book of Revelation paints a picture of ... have tossed it off as mere rubbish, but Yisrayl Hawkins says that is because ...
(Date:10/13/2017)... ... ... “America On The Brink”: the Christian history of the United States and the ... published author, William Nowers. Captain Nowers and his wife, Millie, have six children, ... in the Navy. Following his career as a naval aviator and carrier pilot, ...
(Date:10/12/2017)... ... October 12, 2017 , ... The ... demand of today’s consumer and regulatory authorities worldwide. From Children’s to Adults 50+, ... to meet the highest standard. , These products are also: Gluten Free, ...
Breaking Medicine News(10 mins):